Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amiel Moshfegh

Vascular & Interventional Radiology Commerce, CA Medical Doctor

NPI 1144539644 CMS profile 278500

2250 S Atlantic Blvd Ste G, Commerce, CA 90040

Open in the dashboard

General payments

$201,880

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amiel Moshfegh of Commerce, CA is reported in the CMS Open Payments database as having received $201,880 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82,067 9
2024 General $81,804 19
2023 General $31,707 32
2022 General $1,437 36
2021 General $1,972 71
2020 General $1,027 44
2019 General $1,865 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amiel Moshfegh
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Amiel Moshfegh were reported at $82,067. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Amiel Moshfegh Vascular & Interventional Radiology median Middle half National median
2019 $1,865 $422 $125–$1,555 $163
2020 $1,027 $200 $68–$652 $114
2021 $1,972 $280 $99–$866 $132
2022 $1,437 $433 $137–$1,497 $149
2023 $31,707 $506 $152–$2,019 $160
2024 $81,804 $556 $175–$1,930 $164
2025 $82,067 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $194,812 21 payments
  2. Abbott Laboratories $4,280 137 payments
  3. Philips Electronics North America Corporation $1,228 48 payments
  4. Medtronic, Inc. $478 20 payments
  5. Medtronic Vascular, Inc. $344 34 payments
  6. Boston Scientific Corporation $223 6 payments
  7. Veryan Medical Incorporated $166 3 payments
  8. Dova Pharmaceuticals $123 1 payment
  9. Bard Peripheral Vascular, Inc. $87 2 payments
  10. Becton, Dickinson and Company $68 3 payments
  11. Other $71 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $194,417 9 payments
  2. Food and Beverage $7,463 269 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $112,500 6 payments
  2. Auryon Laser System 100-120 Vac Cv $81,917 3 payments
  3. Perclose ProGlide suture mediated closure system Vascular $1,394 42 payments
  4. Perclose ProGlide suture mediated closure system Vascular $1,238 43 payments
  5. Supera peripheral stent system $840 30 payments
  6. AURYON LASER SYSTEM 100-120 VAC Pad $395 12 payments
  7. PERCLOSE PROGLIDE $380 8 payments
  8. (4067) Tack Endo Sys BTK $361 10 payments
  9. Perclose ProStyle $246 4 payments
  10. (6576) Laser serv and other $236 6 payments
  11. Other $2,373 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

98

Median for Interventional Radiology: 38

Drug cost

$14,894

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 12 $14,095
Clopidogrel Clopidogrel Bisulfate Brand 86 $799

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$7,783,459

Medicare's payments for the services billed

Medicare patients

844

Average age 72

Services billed

7,821

488 women, 356 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 35%
Chronic kidney disease 34%
Heart failure 25%
Depression 23%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record